Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 fosmanogepix versus caspofungin/fluconazole for candidemia or invasive candidiasis
CTR20252015Phase 3Active
- Sponsor
- Basilea Pharmaceutica
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fosmanogepix in candidemia, invasive candidiasis, sponsored by Basilea Pharmaceutica. Started Apr 2026; status: active.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on CTR20252015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252015.